Advertisement

Journal of Neural Transmission

, Volume 64, Issue 2, pp 93–103 | Cite as

L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum

  • M. Guttman
  • P. Seeman
Original Papers

Summary

Striatal dopamine receptors were studied using [3H]-spiperone in postmortem tissues of thirty-six patients with Parkinson's Disease. Each tissue was analyzed by the receptor saturation method. In non-treated patients, the D2 dopamine receptor density was elevated in the caudate nucleus and putamen compared to controls. In L-DOPA-treated patients, the receptor density was the same as controls. The dissociation constant for [3H]-spiperone was similar in all groups. The elevated density of D2 receptors in non-treated patients may indicate dopaminergic supersensitivity in this disease. The elevated density was reversed with dopamine agonist therapy, but the density was not lower than control tissues.

Keywords

Dopamine Agonist Caudate Nucleus Receptor Density Striatal Dopamine Agonist Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer, W., Riederer, P.: Parkinson's Disease, p. 32. Wien-New York: Springer. 1983.Google Scholar
  2. Bokobza, G., Ruberg, M., Scatton, B., Javoy-Agid, F., Agid, Y.:3H-spiperone binding, dopamine and HVA concentrations in Parkinson's Disease and supranuclear palsy. Eur. J. Pharm.99, 167–175 (1984).Google Scholar
  3. Ezrin-Waters, C., Seeman, P.: L-Dopa reversal of hyperdopaminergic behaviour. Life Sci.22, 1027–1032 (1978).Google Scholar
  4. Friedhoff, A., Bonnet, K., Rosengarten, H.: Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-Dopa. Res. Commun. Chem. Pathol. Pharmacol.16, 411–423 (1977).Google Scholar
  5. Jackson, D., Jenkins, O. F., Malor, R., Christie, M. J., Gregory, P.: Chronic L-Dopa treatment of rats and mice does not change the sensitivity of post synaptic dopamine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol.324, 271–274 (1983).Google Scholar
  6. Lee, T., Seeman, P., Rajput, A., Farley, I., Hornykiewicz, O.: Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature273, 59–61 (1978).Google Scholar
  7. List, S., Seeman, P.: Dopamine agonists reverse the elevated3H-neuroleptic binding in neuroleptic-pretreated rats. Life Sci.24, 1447–1452 (1979).Google Scholar
  8. Olsen, R., Reisine, T., Yamamura, H.: Neurotransmitter receptors-biochemistry and alterations in neuropsychiatric disorders. Life Sci.27, 801–808 (1980).Google Scholar
  9. Pycock, C., Dawbarn, D., O'Shaughnessy, C.: Behavioral and biochemical changes following chronic administration of L-Dopa to rats. Eur. J. Pharmacol.79, 201–215 (1982).Google Scholar
  10. Quik, M., Spokes, E., MacKay, A., Bannister, R.: Alterations in3H-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's Disease. J. Neurol. Sci.43, 429–437 (1979).Google Scholar
  11. Reches, A., Wagner, H., Jackson-Lewis, V., Yablonskaya-Alter, E., Fahn, S.: Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology34, 1208–1212 (1984).Google Scholar
  12. Reches, A., Wagner, R., Jackson, V., Yablonskaya-Alter, E., Fahn, S.: Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment. Brain Res.275, 183–185 (1983).Google Scholar
  13. Reches, A., Wagner, H., Jiang, D., Jackson, V., Fahn, S.: The effect of chronic L-Dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain. Life Sci.31, 37–44 (1982).Google Scholar
  14. Reisine, T., Fields, J., Yamamura, H.: Neurotransmitter receptor alterations in Parkinson's Disease. Life Sci.21, 335–344 (1977).Google Scholar
  15. Riederer, P., Jellinger, K.: Morphologie und Pathobiochemie der Parkinson-Krankheit. In: Pathophysiologie, Klinik und Therapie des Parkinsonismus (Gänshirt, G., ed.), pp. 31–50. Basel: Roche. 1983.Google Scholar
  16. Rinne, U., Rinne, J. O., Rinne, J. K., Laakso, K., Laihinen, A., Lonnberg, P.: Brain receptor changes in Parkinson's Disease in relation to the disease process and treatment. J. Neural Transm. Suppl. 18, pp. 279–286. Wien-New York: Springer. 1983.Google Scholar
  17. Rinne, U.: Brain neurotransmitter receptors in Parkinson's disease. In: Movement Disorders (Marsden, C., Fahn, S., eds.), pp. 59–74. Butterworth. 1982.Google Scholar
  18. Rinne, U.: Treatment of Parkinson's Disease: problems with a progressing disease. J. Neural Transm.51, 161–174 (1981 a).Google Scholar
  19. Rinne, U., Lonnberg, P., Koskinen, V.: Dopamine receptors in the Parkinsonian brain. J. Neural Transm.51, 97–106 (1981 b).Google Scholar
  20. Rinne, U., Koskinen, V., Lonnberg, P.: Neurotransmitter receptors in the Parkinsonian brain. In: Parkinson's Disease-Current Progress, Problems and Management (Rinne, U., Klinger, M., Stamm, G., eds), pp. 93–107. Elsevier/North-Holland Biomedical Press. 1980.Google Scholar
  21. Rinne, U., Sonninen, V., Laaksonen, K.: Responses of brain neurochemistry to Levodopa treatment in Parkinson's Disease. Adv. Neurol.24, 259–274 (1979).Google Scholar
  22. Schneider, M., Murrin, L., Pfeiffer, R., Deupree, J.: Dopamine receptors: effects of chronic L-Dopa and bromocriptine treatment in an animal model of Parkinson's disease. Clin. Neuropharm.7, 247–257 (1984).Google Scholar
  23. Seeman, P., Ulpian, C., Wreggett, K., Wells, J.: Dopamine receptor parameters detected by3H-spiperone depend on tissue concentration: analysis and examples. J. Neurochem.43, 221–235 (1984).Google Scholar
  24. Seeman, P.: Brain dopamine receptors. Pharmacol. Rev.32, 229–313 (1980).Google Scholar
  25. Staunton, D., Magistretti, P., Koob, G., Shoemaker, W., Bloom, F.: Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive. Nature299, 72–74 (1982).Google Scholar
  26. Suga, M.: Effect of long-term L-DOPA administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats. Life Sci.27, 878–883 (1980).Google Scholar
  27. Winkler, M., Barl, S., Whetsell, W., Yahr, M.: Spiroperidol binding in the human caudate nucleus. J. Neural Transm.S 16, 45–51 (1980).Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • M. Guttman
    • 1
  • P. Seeman
    • 2
  1. 1.Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada

Personalised recommendations